UNITED LAB (03933) announced that the Investigational New Drug (IND) application for its Class 1 innovative drug TUL321 Capsule, developed by its wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd., has been approved by the U.S. Food and Drug Administration (FDA), with the IND number 180385. Additionally, a clinical trial application has been submitted in China and has been accepted. TUL321 Capsule is a new-generation complement factor B (CFB) inhibitor. The complement system is a vital component of innate immunity; its activation products facilitate functions such as opsonization, cell lysis, inflammation mediation, immune response regulation, and clearance of immune complexes, primarily activated through the classical, lectin, and alternative pathways. CFB is a core rate-limiting serine protease precursor in the alternative pathway of the complement system. Abnormal activation under pathological conditions can lead to uncontrolled alternative pathway activity, mediating tissue damage and thereby triggering various diseases. Preclinical studies indicate that TUL321 Capsule features a unique target binding mode and excellent permeability characteristics, demonstrating superior therapeutic potential compared to similar drugs in treating conditions such as paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, age-related macular degeneration, multiple sclerosis, and myasthenia gravis. This approval marks another significant milestone in the company's innovative research and development within the autoimmune disease treatment sector. Moving forward, the company will continue to dedicate efforts to new product development, aiming to enhance its competitiveness and creativity in the pharmaceutical industry, which is expected to generate greater returns for the company and its shareholders.
Comments